Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 6, November-December, p. 987–992

Publication type: original article

Language: English

The Lifetime Prevalence of Anxiety Disorders Among Patients with Irritable Bowel Syndrome

Magdalena Grzesiak1,A,B,C,D,F, Jan A. Beszłej1,A,C,D,F, Agata Mulak2,A,B,D,F, Marcin Szechiński1,B,E,F, Monika Szewczuk-Bogusławska1,B,E,F, Ewa Waszczuk2,A,B,E,F, Monika Kantorska1,C,E,F, Dorota Frydecka1,C,E,F,G

1 Department of Psychiatry, Wroclaw Medical University, Poland

2 Department of Gastroenterology and Hepatology, Wroclaw Medical University, Poland

Abstract

Background. The prevalence of irritable bowel syndrome (IBS), the most common functional gastrointestinal disorder, ranges from 10% to 20% in the general population. It is estimated that from 40% to 90% of persons with a diagnosis of IBS suffer from mental disorders, mainly anxiety and depressive disorders.
Objectives. . The aim of the study was to assess the lifetime prevalence of anxiety disorders in IBS patients and to compare it with the prevalence of these disorders in a control group of patients with gastroesophageal reflux disease (GERD).
Material and Methods. The study included 106 patients with IBS and 53 patients with GERD. IBS was diagnosed according to the Rome II criteria after a basic evaluation to exclude an organic disease. Anxiety disorders were diagnosed using the Composite International Diagnostic Interview (CIDI) in accordance with ICD-10 diagnostic criteria.
Results. Anxiety disorders during the patient’s lifetime were diagnosed in 50 IBS patients (47%). Specific phobias occurred in 23.5% of them, social phobias in 10.4 %, generalized anxiety disorder in 10.4%, panic disorder in 3.8% and agoraphobia in 8.5%. In the control group with GERD, anxiety disorders during the subject’s lifetime were diagnosed in 30% of the group. The difference in the prevalence of anxiety disorders between patients with IBS and GERD was statistically significant (p < 0.05).
Conclusion. The lifetime prevalence of anxiety disorders in IBS patients was higher than in the control group with GERD (47% vs. 30%). The prevalence rate of anxiety disorders in the control group with GERD was similar to the prevalence rate in the general population.

Key words

anxiety disorders, irritable bowel syndrome, CIDI.

References (37)

  1. Longstreth GF, Thompson WG, Chey WD: Functional bowel disorders. Gastroenterology 2006, 130, 1480– –1491.
  2. Mulak A, Waszczuk E, Paradowski: Irritable bowel syndrome as an interdisciplinary clinical problem. Adv Clin Exp Med 2008, 17, 667–675.
  3. Drossman DA, Camillieri M, Mayer E, Whitehead WE: AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123, 2108–2131.
  4. Nicholl BI, Halder SL, Macfarlane GJ, Thompson DG, O’Brien S, Musleh M, McBeth K: Psychosocial risk markers for new onset irritable bowel syndrome-results of a large perspective population-based study. Pain 2007, 8, 161–169.
  5. Ruigomez A, Wallender MA, Johansson S, Garcia-Rodrigez LA: One-year follow-up of newly diagnosed irritable bowel patients. Aliment Pharmacol Ther 1999, 13, 1097–1102.
  6. Heitkemper M, Jarrett M, Bond EF, Chang L: Impact of sex and gender on irritable bowel syndrome. Biol Res Nurs 2003, 5, 56–65.
  7. Mulak A, Taché Y: Sex difference in irritable bowel syndrome: do gonadal hormones play a role? Gastroenterol Pol 2010, 17, 89–97.
  8. Drossman DA, Li Z, Andruzzi E, Temple R, Talley NJ, Thompson WG, Whitehead WE, Janssen J, FunchJensen P, Carazziari E, Richter JE, Koch GG US: householder survey of functional gastrointestinal disorders. Prevalence, socialdemography and health impact. Dig Dis Sci 1993, 38, 1569–1580.
  9. Camilleri M: Management of irritable bowel syndrome. Gastroenterology 2001, 120, 652–668.
  10. Whitehead WE, Palsson O, Jones KR: Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002, 122, 1140–1156.
  11. Creed F, Ratcliffe J, Fernandes L, Palmer S, Rigby C, Read N, Thompson DG: Outcome in severe irritable bowel syndrome with and without accompanying depressive, panic and neurasthenic disorders. Br J Psychiatry 2005, 186, 507–515.
  12. Lydiard RB, Fossey MD, Marsh W, Ballenger JC: Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics 1993, 34, 229–234.
  13. Guthrie E, Creed F, Fernandes L, Ratcliffe J, Van der Jagt J, Martin J, Howlett S, Read N, Barlow J, Thompson D, Tomenson: Cluster analysis of symptoms and health seeking behaviour differentiates subgroups of patients with severe irritable bowel syndrome. Gut 2003, 52, 1616–1622.
  14. Świątkowski M, Rybakowski J: Depression and T lymphocytes in patients with irritable bowel syndrome. J Affective Disorders 1993, 28, 199–202.
  15. Sułkowska A, Borys B, Majkowicz M, Sułkowski B: Emotional background of irritable bowel syndrome analysis based on the results of the study using MMPI. Gastroenterol Pol 2003, 10, 331–334.
  16. Drossman DA, Talley NY, Whitehead WE, Corazziari E: Research diagnostic questions for functional gastrointestinal disorders: Rome II Modular Questionnaire: Investigations and Respondent Form. In: Rome II the Functional Gastrointestinal Disorders. Eds.: Drossman DA, Corazziari E, Talley NY, Thomson WG. McLean. Degnon Associates 2002, ed. 2nd, 669–714.
  17. Klasyfikacja zaburzeń psychicznych i zaburzeń zachowania w ICD-10. Uniwersyteckie Wydawnictwo Medyczne Versalius. Instytut Psychiatrii i Neurologii. Kraków–Warszawa 1997.
  18. World Health Organization. The Composite International Diagnostic Interview. WHO. Geneva 1993.
  19. Wittchen HU: Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI). A critical review. J Psychiatric Research 1994, 28, 57–84.
  20. Wittchen HU, Lachner G, Wunderlich U, Pfister H: Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI). Soc Psychiatry Psychiatr Epidemiol 1998, 33, 568–578.
  21. Walker EA, Roy-Byrne PP, Katon WJ: Psychiatric illness and irritable bowel syndrome. A comparison with inflammatory bowel disease. Am J Psychiatry 1990, 147, 1656–1661.
  22. Lydiard RB, Fossey MD, Marsh W, Ballenger JC: Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics 1993, 34, 229–234.
  23. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distribution of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62, 593–602.
  24. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshelman S, Wittchen HU, Kendler KS: Lifetime and 12-month prevalence of DSM-II-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994, 51, 8–19.
  25. Lee S, Wu J, Ma Y, Tsang A, Guo WJ, Sung J: Irritable Bowel Syndrome is Strongly Associated with Generalized Anxiety Disorder: A Community Study. Alimentary Pharmacology Therapeutics 2009, 30, 643–651.
  26. Grzesiak M, Beszłej JA, Szechiński M, Szewczuk-Bogusławska M, Waszczuk E, Mulak A, Kantorska M: Depressive disorders in patients with irritable bowel syndrome diagnosed using the Composite International Diagnostic Interview (CIDI). Adv Clin Exp Med 2010, 19, 601–605.
  27. Lyriad RB: Irritable bowel syndrome, anxiety and depression: What are the links? J Clin Psychiatry 2001, 62, 38–45.
  28. Cole JA, Rothman KJ, Cabral HJ, Zhang Y, Farraye F: Migraine, fibromyalgia and depression among people with IBS: a prevalence study. BMC Gastroenterology 2006, 6, 26–34.
  29. Ladep NG, Obindo TJ, Audu MD, Okeke EN, Malu AO: Depression in patients with irritable bowel syndrome in Jos, Nigeria. World J Gastroenterol 2006, 48, 7844–7847.
  30. Walker EA, Roy-Byrne PP, Katon WJ, Li L, Amos D, Jiranek G: Psychiatric illness and irritable bowel syndrome: a comparison with inflammatory bowel disease. Am J Psych 1990, 147, 1656–1661.
  31. Lydiard RB, Fossey MD, Marsh W, Ballenger JC: Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics 1993, 34, 229–234.
  32. Hillilä MT, Siivola MT, Färkkilä MA: Comorbidity and use of health-care services among irritable bowel syndrome sufferers. Scand J Gastroenterol 2007, 42, 799–806.
  33. Mykletun A, Jacka F, Williams L, Pasco J, Henry M, Nicholson GC, Kotowicz MA, Berk M: Prevalence of mood and anxiety disorder in self-reported irritable bowel syndrome (IBS). An epidemiological population based study of women. BMC Gastroenterology 2010, 10, 88–97.
  34. Spiegel DR, Kolb R: Treatment of irritable bowel syndrome with comorbid anxiety symptoms with mirtazapine. Clin Neuropharmacol 2011, 34, 36–38.
  35. Jarret ME, Burr RL, Cain KC, Hertig V, Weisman P, Heitkemper MM: Anxiety and depression are related to autonomic nervous system function in women with irritable bowel syndrome. Digestive Diseases Sciences 2003, 48, 386–394.
  36. Hao JX, Han M, Duan LP, Ge Y, Huang YQ: Psychiatric comorbidities in patients referred for irritable bowel syndrome. Zhonghua Yi Xue Za Zhi 2011, 91, 1886–1890.
  37. Kwon JG, Park KS, Park JH, Park JM, Park CH, Lee KJ, Park HJ, Rhee JC: Korean Society of Neurogastroenterology and Motility: Guidelines for the treatment of irritable bowel syndrome. Korean J Gastroenterol 2011, 57, 82–99.
© Wroclaw Medical University